REBACIN® is an optional intervention for persistent high‐risk human papillomavirus infection: A retrospective analysis of 364 patients

Yang, Ying; Teng, Hu; Ming, Xiu; Yang, Eun Jung; Min, Wenjiao; Li, Zhengyu

doi:10.1002/ijgo.13385

Cited by 5 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…REBACIN® is a recently discovered drug that has demonstrated a potent effect on clearing HPV infection. Enriched with the bioactive factor AVF, clinical trials and retrospective studies have confirmed its efficacy in treating HPV infection 361,362 . Recent research has also shown that REBACIN® can clear HPV infection by inhibiting the E6/E7 oncogenes 363 .…”

Section: Therapeutic Interventionsmentioning

confidence: 98%

“…Enriched with the bioactive factor AVF, clinical trials and retrospective studies have confirmed its efficacy in treating HPV infection. 361 , 362 Recent research has also shown that REBACIN® can clear HPV infection by inhibiting the E6/E7 oncogenes. 363 Considering the influence of vaginal microbiota on HPV infection and cervical lesions, modulating the VMB appears to be a practical approach for assisting in the clearance of HPV infection.…”

Section: Therapeutic Interventionsmentioning

confidence: 99%

See 1 more Smart Citation

Human papillomavirus associated cervical lesion: pathogenesis and therapeutic interventions

Ye,

Zheng,

et al. 2023

MedComm

View full text Add to dashboard Cite

Human papillomavirus (HPV) is the most prevalent sexually transmitted virus globally. Persistent high‐risk HPV infection can result in cervical precancerous lesions and cervical cancer, with 70% of cervical cancer cases associated with high‐risk types HPV16 and 18. HPV infection imposes a significant financial and psychological burden. Therefore, studying methods to eradicate HPV infection and halt the progression of precancerous lesions remains crucial. This review comprehensively explores the mechanisms underlying HPV‐related cervical lesions, including the viral life cycle, immune factors, epithelial cell malignant transformation, and host and environmental contributing factors. Additionally, we provide a comprehensive overview of treatment methods for HPV‐related cervical precancerous lesions and cervical cancer. Our focus is on immunotherapy, encompassing HPV therapeutic vaccines, immune checkpoint inhibitors, and advanced adoptive T cell therapy. Furthermore, we summarize the commonly employed drugs and other nonsurgical treatments currently utilized in clinical practice for managing HPV infection and associated cervical lesions. Gene editing technology is currently undergoing clinical research and, although not yet employed officially in clinical treatment of cervical lesions, numerous preclinical studies have substantiated its efficacy. Therefore, it holds promise as a precise treatment strategy for HPV‐related cervical lesions.

show abstract

Section: Therapeutic Interventionsmentioning

confidence: 98%

Section: Therapeutic Interventionsmentioning

confidence: 99%

Human papillomavirus associated cervical lesion: pathogenesis and therapeutic interventions

Ye,

Zheng,

et al. 2023

MedComm

View full text Add to dashboard Cite

show abstract

“…Mechanistically, REBACIN ® inhibits the mRNA transcription of high-risk HPV E6 and E7 oncoproteins in mice [331]. In addition, Yang et al performed a retrospective analysis and a meta-analysis and found that REBACIN ® showed better efficacy than IFN for treating a persistent high-risk HVP infection [332]. Yuen et al performed a phase one RCT to test the anti-HBV activity of an SBA class CAM, NVR 3-778, in patients with chronic HBV infection without cirrhosis [333].…”

Section: Clinical Translation Of Nuclear Transport Inhibitors Against Viral Infectionsmentioning

confidence: 99%

How SARS-CoV-2 and Other Viruses Build an Invasion Route to Hijack the Host Nucleocytoplasmic Trafficking System

Sajidah

Lim

Wong

2021

Cells

View full text Add to dashboard Cite

The host nucleocytoplasmic trafficking system is often hijacked by viruses to accomplish their replication and to suppress the host immune response. Viruses encode many factors that interact with the host nuclear transport receptors (NTRs) and the nucleoporins of the nuclear pore complex (NPC) to access the host nucleus. In this review, we discuss the viral factors and the host factors involved in the nuclear import and export of viral components. As nucleocytoplasmic shuttling is vital for the replication of many viruses, we also review several drugs that target the host nuclear transport machinery and discuss their feasibility for use in antiviral treatment.

show abstract

“…Meanwhile, combination antiretroviral therapy (cART), which comprised five nucleoside analogue reverse transcriptase inhibitors (zidovudine, didanosine, zalcitabine, stavudine, and lamivudine), two non-nucleoside reverse transcriptase inhibitors (delavirdine and nevirapine), and four protease inhibitors (saquinavir, ritonavir, indinavir, and nelfinavir), was able to elicit HPVE6-specific immunological response with enhanced CD4 T cell count in HIV patients [ 229 , 230 ]. A Phase II clinical trial showed that the application of a proprietary antiviral agent, REBACIN ® cream (REBACIN Vaginal Gel; Hainan SR-Bio Pharma Co., Ltd., Hainan, China) onto intravaginal lesions could effectively suppress HPV oncogenes expression [ 231 ].…”

Section: Treatment Regimensmentioning

confidence: 99%

Current Updates on Cancer-Causing Types of Human Papillomaviruses (HPVs) in East, Southeast, and South Asia

Xia

Long

et al. 2021

Cancers

View full text Add to dashboard Cite

Human papillomavirus (HPV) infection remains one of the most prominent cancer-causing DNA viruses, contributing to approximately 5% of human cancers. While association between HPV and cervical cancers has been well-established, evidence on the attribution of head and neck cancers (HNC) to HPV have been increasing in recent years. Among the cancer-causing HPV genotypes, HPV16 and 18 remain the major contributors to cancers across the globe. Nonetheless, the distribution of HPV genotypes in ethnically, geographically, and socio-economically diverse East, Southeast, and South Asia may differ from other parts of the world. In this review, we garner and provide updated insight into various aspects of HPV reported in recent years (2015–2021) in these regions. We included: (i) the HPV genotypes detected in normal cancers of the uterine cervix and head and neck, as well as the distribution of the HPV genotypes by geography and age groups; (ii) the laboratory diagnostic methods and treatment regimens used within these regions; and (iii) the oncogenic properties of HPV prototypes and their variants contributing to carcinogenesis. More importantly, we also unveil the similarities and discrepancies between these aspects, the areas lacking study, and the challenges faced in HPV studies.

show abstract

REBACIN® is an optional intervention for persistent high‐risk human papillomavirus infection: A retrospective analysis of 364 patients

Cited by 5 publications

References 19 publications

Human papillomavirus associated cervical lesion: pathogenesis and therapeutic interventions

Human papillomavirus associated cervical lesion: pathogenesis and therapeutic interventions

How SARS-CoV-2 and Other Viruses Build an Invasion Route to Hijack the Host Nucleocytoplasmic Trafficking System

Current Updates on Cancer-Causing Types of Human Papillomaviruses (HPVs) in East, Southeast, and South Asia

Contact Info

Product

Resources

About